Gemcitabine and Docetaxel as a Second-Line Treatment in Advanced Soft Tissue Sarcomas

Article Figures & Data

Download figure
Open in new tab
Download powerpoint
Fig. 1.
Over all survival of All Patients (OAS).

Table 1.

Patients’ Characteristics.

Characteristics		No. of patients (%)
Age	Median (range)	48 (18–68)
Sex	Male: Female	23:17 (1.35:1)
Disease
	Locally advanced	10 (25)
	Metastatic-single organ	20 (50)
	Metastatic-multiple organs	10 (25)
Histology
	Leiomyosarcoma	7 (17.5)
	Liposarcoma	9 (22.5)
	Malignant fibrous histocytoma	5 (12.5)
	Fibrosarcoma	7 (17.5)
	Synovial sarcoma	3 (7.5)
	Undifferentiated sarcoma	4 (10)
	Others	5(12.5)
Performance status (PS)
	0	15 (37.5)
	1	19 (47.5)
	2	6 (15)
Site of metastasis
	Lung	24 (60)
	Liver	3 (7.5)
	Bone	3 (7.5)
primary tumor location
	Limbs	14 (35)
	Uterine	7 (17.5)
	Retroperitoneal	8 (20)
	Organ except uterine corpus	11 (27.5)
Previous treatment
	Surgery	10 (25)
	Radiotherapy	11 (27.5)
	Chemotherapy	40 (100)
Previous chemotherapy
	Adriamycin	7 (17.5)
	Ifosfamide	15 (37.5)
	Adriamycin+ Ifosfamide	18 (45)

Table 2.

Toxicity of Chemotherapy

Effects of toxicity	G1 No. of patients (%)	G2 No. of patients (%)	G3 No. of patients (%)	G4 No. of patients (%)
Thrombocytopenia	7 (17.5)	5(12.5)	3 (7.5)	0
Neutropnenia	7 (17.5)	8 (20)	3 (7.5)	1 (2.5)
Anemia	6(15)	4 (10)	1 (2.5)	0
Diarrhea	4 (10)	3 (7.5)	1 (2.5)	0
Fatigue	10 (25)	7 (17.5)	0	0
Mucositis	10 (25)	8 (20)	0	0
Allergy	2 (5)	1 (2.5)	0	0
Pulmonary	3 (7.5)	1 (2.5)	0	0